Combination chemo-radiotherapy for residual, recurrent or inoperable XXXX : E.C.O.G. study (EST 3276).

@entity1 @entity137 @entity188 @entity16418 @entity1487
Thirty evaluated @entity1 were randomized to either continuous radiation + @entity1487 (16 @entity1 ), or split-course radiation + @entity1487 (14 @entity1 ) for the treatment of residual, recurrent, or inoperable @entity188 or recto-sigmoid. Twenty-one of these @entity1 received maintenance @entity16418 + @entity1487 chemotherapy following radiation. Entry was terminated when late treatment reactions were seen in the precursor pilot study. Twenty-four of the @entity1 have died; the estimated median survival is 17 months in each of the treatment arms. Performance status was the only significant prognostic factor for survival. The rate of severe, acute reactions during the radiation treatment period was higher for the continuous-course than for the split-course regimen (69 vs. 21%, p = .01). The rates of severe late treatment reactions, 23% (7 of 30), and severe chemotherapy @entity137 , 48%, were similar for the two treatment programs. Late treatment reactions, primarily bowel complications, were seen from 3 to 23 months after radiation in 3 @entity1 treated with continuous course, and 4 @entity1 treated with split course. Ten of 21 @entity1 (48%) who received maintenance chemotherapy had severe or worse @entity137 . @entity137 was seen for 6 of 12 continuous-course, and 4 of 9 split-course @entity1 . Twenty-seven @entity1 have had disease progression, and the median length of disease control is 11 months.
